1. Home
  2. MRM vs SNTI Comparison

MRM vs SNTI Comparison

Compare MRM & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MEDIROM Healthcare Technologies Inc.

MRM

MEDIROM Healthcare Technologies Inc.

N/A

Current Price

$0.83

Market Cap

7.6M

ML Signal

N/A

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

HOLD

Current Price

$0.31

Market Cap

10.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRM
SNTI
Founded
2000
2016
Country
Japan
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.6M
10.4M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
MRM
SNTI
Price
$0.83
$0.31
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.50
AVG Volume (30 Days)
10.2K
194.8K
Earning Date
05-19-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
77.31
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$32.01
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.79
$0.29
52 Week High
$4.45
$2.88

Technical Indicators

Market Signals
Indicator
MRM
SNTI
Relative Strength Index (RSI) 34.48 29.59
Support Level $0.81 N/A
Resistance Level $1.02 $0.40
Average True Range (ATR) 0.06 0.04
MACD -0.01 0.00
Stochastic Oscillator 28.80 7.74

Price Performance

Historical Comparison
MRM
SNTI

About MRM MEDIROM Healthcare Technologies Inc.

MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.

About SNTI Senti Biosciences Inc.

Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).

Share on Social Networks: